NIH Publication No. 01-3670, May 2001 - 40 p.Introduction
Background
LDL Cholesterol: The Primary Target of Therapy
Risk Assessment: First Step in Risk Management
Method of risk assessment: counting major
risk factors and estimating 10-year CHD risk
Role of other risk factors in risk assessment
Metabolic syndrome
The link between risk assessment and cost
effectiveness
Primary Prevention With LDL-Lowering Therapy
Secondary Prevention With LDL-Lowering Therapy
LDL-Lowering Therapy in Three Risk Categories
CHD and CHD risk equivalents
Multiple (2+) risk factors and 10-year risk ²20%
Zero to one risk factor
Therapeutic Lifestyle Changes in LDL-Lowering Therapy
Drug Therapy to Achieve LDL-Cholesterol Goals
Secondary prevention: drug therapy for CHD and
CHD risk equivalents
LDL-lowering drug therapy for primary prevention
Benefit Beyond LDL Lowering: The Metabolic
Syndrome as a Secondary Target of Therapy
Management of underlying causes of the metabolic
syndrome
Specific Treatment of Lipid and Non-Lipid Risk
Factors
Special Issues
Management of Specific Dyslipidemias
Special Considerations for Different Population Groups
Adherence to LDL-Lowering Therapy
Appendix
Shared Features of ATP III and ATP II
Estimating 10-Year Risk for Men and Women
